{
    "2020-10-19": [
        [
            {
                "time": "",
                "original_text": "不惧调整 公募基金仍重点掘金医药",
                "features": {
                    "keywords": [
                        "公募基金",
                        "医药"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：冠脉支架国采方案落地 头部企业有望相对受益",
                "features": {
                    "keywords": [
                        "医药生物",
                        "冠脉支架",
                        "国采",
                        "头部企业"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业报告：持续看好流感及肺炎相关疫苗销售 关注医药三季报业绩主线",
                "features": {
                    "keywords": [
                        "医药生物",
                        "流感",
                        "肺炎",
                        "疫苗",
                        "三季报"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物(300122)：业绩持续高增长 研发进入收获期",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "业绩",
                        "研发",
                        "高增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业跨市场周报：冠脉支架全国集采政策落地 未来或催生两大高耗投资方向",
                "features": {
                    "keywords": [
                        "医药生物",
                        "冠脉支架",
                        "集采",
                        "高耗投资"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物(300122)：Q3业绩超预期 新冠疫苗研发快速推进",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "Q3",
                        "新冠疫苗",
                        "研发"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "智飞生物：前三季度营收及归母净利已超2019年全年 经营性现金流同比增长逾300%",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "营收",
                        "净利",
                        "现金流"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "创业板指翻绿，迈瑞医疗、智飞生物、爱尔眼科、亿纬锂能均走低",
                "features": {
                    "keywords": [
                        "创业板指",
                        "迈瑞医疗",
                        "智飞生物",
                        "爱尔眼科",
                        "亿纬锂能"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "67股获券商买入评级，众信旅游目标涨幅达82.64%",
                "features": {
                    "keywords": [
                        "券商",
                        "买入评级",
                        "众信旅游"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "旅游"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}